Lead (Pb), Pb (Lead)
Lead, Urine (PBU)
Legionella Culture (LEGI), 50008-LEGI
Flaxseed, Lium usitatissimum, Linseed, IgE, Serum (LINS)
This test does not include a pathology consult. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge.
This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for application of all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.
Third Generation LH assay
Ultrasensitive LH assay
Lyme CNS Infection IgG Screen, CSF
Lyme CNS Infection IgG, S
Reflex test: Lyme CNS Infection, IgG Ab Index
This test begins with IgG screening of the spinal fluid (CSF) specimen. If the screen is negative, no additional testing will be performed.
If the screen is positive, the paired CSF and serum specimens will be used to establish the antibody index. In order to establish the antibody index, the paired serum and CSF samples (collected within 24 hours of each other) are tested on the same run using quantitative assays to determine levels for the following analytes:
1. Anti-Borrelia species IgG levels in CSF and serum
2. Total IgG in CSF and serum
3. Albumin in CSF and serum
These additional tests are necessary in order to normalize the level of anti-Borrelia antibodies to total IgG and albumin in the CSF and establish the antibody index ratio of anti-Borrelia antibodies in CSF-to-serum. This testing is performed at an additional charge.
Borrelia afzelii; Borrelia burgdorferi by PCR; Borrelia burgdorferi sensu lato genogroup; Borrelia garini;
Borrelia mayonii; Lyme Disease; Lyme Disease (PCR); Lyme Disease,CSF; PCR; Sensu lato group; Spirochetes; Tick-Borne Diseases
Previous serology positivity for Borrelia burgdorferi, is a requirement to order this test.All CSF specimens MUST be approved by Dr. Taylor Wahlig or Dr. Sophie Arbefeville prior to sending to Mayo Clinic Labs. For synovial fluid specimens order the in-house test code: LYMEPCR.
B. burgdorferi PCR, B. mayonii PCR, B. garinii/B. afzelii PCR
Lyme confirmation, Lyme IgM, Lyme IgG, B. burgdorferi
IgM and IgG-class antibodies to B. burgdorferi (Lyme disease)
Blastogenesis Antigens Immune Competence Lymphocyte Blastogenesis Antigen Lymphocyte Phytohemagglutiin Lymphocyte Transformation
If insufficient peripheral blood mononuclear cells (PBMCs) are isolated from the patient's sample due to low WBC counts or specimen volume received, selected dilutions or stimulants may not be tested at the discretion of the laboratory to ensure the most reliable results. Testing with 1 stimulant will always be performed. When adequate specimen is available for both stimulants to be tested, an additional test ID will be reflexed and billed separately.
In vitro T-Cell Function
Lymphocyte Blastogenesis Mitogens
Reflex Tests: Additional Flow Stimulant, LPMGF (MGSTM)
If insufficient peripheral blood mononuclear cells (PBMC) are isolated from the patient's sample due to low white blood cell counts or specimen volume received, selected dilutions or stimulants may not be tested at the discretion of the laboratory to ensure the most reliable results. Testing with one stimulant will always be performed. When adequate specimen is available for both stimulants to be tested, an additional test ID will be performed at an additional charge.
Alpha-Fucosidosis, Alpha-Galactosidase Deficiency, Alpha-Mannosidosis, Alpha-N-Acetylgalactosaminidase Deficiency, Arylsulfatase A Deficiency, Arylsulfatase B Deficiency, Aspartylglucosaminuria, Aspartylglycosaminuria, Beta-Galactosidase Deficiency, Beta-Glucuronidase Deficiency, Ceramide Hexosides, Ceramide Trihexosidase, Ceramide Trihexosidase Deficiency, Chondroitin-6-sulfate, Chondroitin-6 sulfate, Dermatan Sulfate, Diffuse Angiokeratoma, Fabry Disease, Fabry's Disease, GAGS (Glycosaminoglycans), Galactose-6-Sulfatase Deficiency, Galactosialidosis, GB3, GL3, Globotriaosylceramide, Glycosaminoglycans (GAGS), GM1 gangliosidosis, GM2 gangliosidosis, Heparan Sulfate, Hunter Syndrome, Hurler Syndrome, Hurler-Scheie Syndrome, I-Cell Disease, Iduronate Sulfatase Deficiency, Iduronidase Deficiency, Keratan Sulfate, LSD, Lysosomal Storage, Lysosomal Storage Disease, Maroteaux Lamy Syndrome, Maroteaux-Lamy Syndrome, Metachromatic Leukodystrophy, Morquio A, Morquio B, MPS I, MPS II, MPS III, MPS IVA, MPS IVB, MPS VI, MPS VII, Mucolipidosis II, Mucolipidosis III, Mucopolysaccharides, Mucopolysaccharidosis, Multiple Sulfatase Deficiency, Oligosaccharides, Oligosaccharidosis, Pompe Disease, Pseudo-Hurler Polydystrophy, Sandhoff Disease, Sanfilippo Syndrome, Scheie Syndrome, Schindler Disease, Sialidosis, Sly Syndrome, Sphingolipids, Sulfatides
This is a general urine screening test for a broad array of lysosomal storage (LSD) and related disorders. Not all LSDs are detectable by this method.
The first step in a diagnostic workup of an individual suspected of having a lysosomal storage disorder (LSD) includes urine analyses for metabolites associated with mucopolysaccharidoses, oligosaccharidoses, disorders of sulfatide degradation, and LSDs with characteristic urine profiles.
This test contains a combined analysis of ceramide trihexosides, mucopolysaccharides, oligosaccharides, and sulfatides. This combined analysis of these disease-specific markers allows for the identification of disorders that may not be picked up using any of the single tests alone.